Skip to content
MarketScale
‹ Back to Industries

Sciences

Let the Space Race Begin Again

NASA successfully launched the most powerful rocket in the world into outer space this week. The Orion spacecraft is headed for the moon, with the goal of returning to earth in less than four weeks. The journey is the first leg of the Artemis I mission, which has the goal of eventually launching spacecraft…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Ryan Duffy · ArtemisNasaOrionSpacelaunch
Share

Key takeaways

01

NASA successfully launched the most powerful rocket in the world into outer space this week.

02

The Orion spacecraft is headed for the moon, with the goal of returning to earth in less than four weeks.

03

The journey is the first leg of the Artemis I mission, which has the goal of eventually launching spacecraft…

NASA successfully launched the most powerful rocket in the world into outer space this week. The Orion spacecraft is headed for the moon, with the goal of returning to earth in less than four weeks.

The journey is the first leg of the Artemis I mission, which has the goal of eventually launching spacecraft from the moon to Mars.

Ryan Duffy, Managing Editor for Payload Space, explained that while this project was more expensive and took longer than expected, it is still a major milestone for NASA and the space exploration industry at large, whether future trips be government of privately funded.

Ryan’s Thoughts:

“This program was not without challenges. Super heavy SLS rocket came way over budget, years behind schedule, but NASA is back in the moonwalking business, or it will be soon, and the Artemis era is upon us. The big difference between Artemis and Apollo, I’d say is the prevalence and increased legitimacy of commercial space.

SpaceX will land at least two crews of Artemis astronauts on the moon. There’s a whole range of NASA-supported, but somewhat self-funded lunar landers and rovers that are headed for the lunar surface. The last thing to watch for toward the end of the decade is China and their moves around building a presence on the moon.

Another, longer-term thing to watch for is that we aren’t stopping on the moon. This time we’re headed for Mars as well.”

About the author

RD
Ryan DuffyManaging Editor

Ryan leads editorial operations at Payload, a new digital media outfit covering the business of policy of space. Payload's flagship product, a daily newsletter, features a combination of original reporting, news curation, and industry analysis.

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

RD
Ryan Duffy

Managing Editor

Ryan leads editorial operations at Payload, a new digital media outfit covering the business of policy of space. Payload's flagship product, a daily newsletter, features a combination of original reporting, news curation, and industry analysis.